News
January 20, 2023
Asep Medical Holdings Inc. Announces Adoption of Long-term Performance Incentive Plan, Grant of Stock Options
January 18, 2023
Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023
December 28, 2022
CLARIFICATION Asep Medical Holdings Inc. Provides Update on its Prior Disclosure Regarding Proprietary Diagnostic & Therapeutic Technologies
December 24, 2022
Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies
December 22, 2022
Asep Inc. Completes Non-Brokered Private Placement of a $330,000 Unsecured Convertible Debenture
December 2, 2022
Asep Medical Holdings Inc. Enters into Commercial Agreement to Acquire SafeCoat Medical Inc.
November 24, 2022
Asep Medical Holdings Inc. Announces Grant of Stock Options
November 23, 2022
Asep Medical Holdings Inc. Announces Listing of its Common Shares on the Frankfurt Stock Exchange
November 7, 2022
Asep Inc. is Granted Patent Approval for its Sepsis Diagnostic Technology in 13 European Countries and Australia
October 4, 2022
Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author Appointed to Asep Inc.’s Board of Directors
July 19, 2022
Asep Medical Inc. Announces Appointment of Dr. Robert E. W. Hancock as CEO and Chairman
June 7, 2022
Asep Medical Holdings Inc. Receives Revocation of Cease Trade Order from the BC Securities Commission.
April 26, 2022
Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.
March 22, 2022
Asep Medical Holdings Inc. Announces Compelling Results of an Independent Sepsis Study Prepared by RTI Health Solutions
March 3, 2022
Asep Medical Holdings Inc. to Hold Online Investor Information Webinar on March 3, 2022
February 19, 2022